SPARCC is an independant entity that is administered and mananaged by clinicans and researchers committed to improving the lives of Canadians who suffer with these chronic debilitating diseases.
SPARCC is pleased to gratefully acknowledge the generous financial contributions from pharmaceutical companies Abbott, Amgen/Pfizer and Janssen, in the form of unrestricted grants, ensuring that our research and activities are conducted without bias towards any one particular company or product.
Funding from these companies provides SPARCC the ability to continue with it's mission and to achieve its long term goals to achieve significant advances in the understanding and management of spondyloarthritis..